ClinicalTrials.gg
Status unknownNCT00006208Updated Jun 24, 2005

A Comparison of Emtricitabine and Stavudine Used With Didanosine Plus Efavirenz in HIV-Infected Patients Who Have Not Taken Anti-HIV Drugs

A Phase 3 interventional study of Efavirenz and Emtricitabine in HIV Infections, sponsored by Triangle Pharmaceuticals. Status unknown at 63 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2005-06-24.

Sponsored by Triangle Pharmaceuticals · Phase 3, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jun 2006), so the status shown — last known as Active, not recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 101 studies testing efavirenz in HIV Infections — none open to participants now, none under way, none of them phase 3. efavirenz · HIV Infections.

Started
2000
with 2 others
Phase 3
28 of 101
none open now
Registered
23rd of 101
by date

Among the 101 studies testing efavirenz in HIV Infections, this one is one of 3 that started in 2000, is one of 28 in phase 3, and was the 23rd registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

None of the 101 studies testing efavirenz in HIV Infections is open now. The open studies under HIV Infections, anywhere →

About efavirenz

efavirenz: first FDA approval 1998 (SUSTIVA), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 101 studies testing efavirenz in HIV Infections as a file.
02

Study summary

The purpose of this study is to compare the safety and effectiveness of emtricitabine and stavudine when given with didanosine plus efavirenz to HIV-infected patients.

03

Conditions studied

  • HIV Infections

Browse trials for

Keywords

  • HIV-1
  • Didanosine
  • Drug Therapy, Combination
  • Reverse Transcriptase Inhibitors
  • Anti-HIV Agents
  • Deoxycytidine
  • efavirenz
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients may be eligible for this study if they:

  • Are at least 18 years old at the time of screening.
  • Have plasma -1 RNA loads (level of HIV in your blood) of 5,000 or more copies/ml at the time of screening.
  • Have not used any anti-HIV therapy for more than 2 days.
  • Have a negative pregnancy test within 22 days of starting study drugs.
  • Can be reached by telephone.

Exclusion criteria

Exclusion Criteria

Patients will not be eligible for this study if they:

  • Are pregnant or breast-feeding.
  • Use alcohol or illegal drugs that, in the opinion of the principal investigator, may interfere with the patient's ability to follow the dosing schedule and protocol evaluations.
  • Are being treated for active tuberculosis.
  • Are using astemizole, cisapride, midazolam, triazolam, ergot derivatives, St. John's wort, or drugs for a mental disorder.
  • Have a history of a serious mental disorder.
  • Are unwilling to use an effective barrier method of during the study (for women who can get pregnant).
  • Have a history of opportunistic infections and cancers (Mycobacterium avium complex, cytomegalovirus, toxoplasmic encephalitis or disseminated toxoplasmosis, cryptosporidiosis, Isospora belli, progressive multifocal leukoencephalopathy, visceral Kaposi's sarcoma, and lymphoma). Patients with past episode of pulmonary tuberculosis, Pneumocystis carinii pneumonia, or isolated cutaneous Kaposi's sarcoma are allowed. Medication for the prevention of PCP (TMP/SMX, nebulized pentamidine, and atovaquone) is allowed.
  • Have peripheral neuropathy (a painful condition affecting the nervous system) or history of peripheral neuropathy.
  • Cannot take medicine by mouth or have severe chronic diarrhea within 30 days before beginning the study.
  • Cannot eat 1 or more meals a day because of chronic nausea, vomiting, or abdominal or esophageal discomfort.
  • Have had a serious illness or injury within 30 days of screening. Treatment must have been completed for 14 days prior to study entry.
  • Have a history of AIDS-defining opportunistic infection, except for tuberculosis or infection of the stomach or intestines.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Masking
Double

Interventions

06

Study locations

63 sites
  • Univ of Alabama at Birmingham
    Birmingham, Alabama 352942050, United States
  • East Bay AIDS Ctr
    Berkeley, California 94705, United States
  • East Bay Clinical Trial Ctr
    Concord, California 94520, United States
  • Mem Med Group Inc
    Long Beach, California 90806, United States
  • AIDS Healthcare Foundation
    Los Angeles, California 90027, United States
  • Orange Coast Med Group
    Newport Beach, California 92663, United States
  • St Lukes Medical Group
    San Diego, California 92101, United States
  • Robert Smith Medical Group
    San Diego, California 92103, United States
  • Saint Francis Mem Hosp / HIV Care
    San Francisco, California 94109, United States
  • Davies Med Ctr
    San Francisco, California 94114, United States
  • Beacon Clinic / Boulder Community Hosp
    Boulder, Colorado 80304, United States
  • Univ of Colorado Health Ctr / Denver Gen Hosp
    Denver, Colorado 80262, United States
  • Blick Med Associates
    Stamford, Connecticut 06901, United States
  • George Washington Univ Med Ctr
    Washington, District of Columbia 20037, United States
  • Physicans Home Service
    Washington, District of Columbia 20037, United States
  • Gary Richmond MD
    Fort Lauderdale, Florida 33316, United States
  • Wohlfeiler, Piperator & King, MD, PA
    Miami Beach, Florida 33139, United States
  • South Miami Hosp
    Miami, Florida 33143, United States
  • Larry Bush
    Palm Springs, Florida 33461, United States
  • Health Positive
    Safety Harbor, Florida 34695, United States
  • Infectious Diseases Associates
    Sarasota, Florida 34239, United States
  • Hillsborough County Health Department
    Tampa, Florida 33602, United States
  • Infectious Disease Research Inst
    Tampa, Florida 33614, United States
  • Ingenix Kern McNeill Decatur
    Atlanta, Georgia 30309, United States
  • Infectious Disease Specialists of Atlanta
    Decatur, Georgia 30033, United States
  • Harbin Clinic
    Rome, Georgia 30165, United States
  • Northstar Med Clinic
    Chicago, Illinois 60657, United States
  • Tulane Univ Med Ctr / Infectious Diseases Sect
    New Orleans, Louisiana 70112, United States
  • Institute of Human Virology
    Baltimore, Maryland 21201, United States
  • New England Med Ctr
    Boston, Massachusetts 02111, United States
  • Fenway Community Health Ctr
    Boston, Massachusetts 02115, United States
  • Abbott-Northwestern Hosp / Clinic 42
    Minneapolis, Minnesota 55404, United States
  • South Jersey Infectious Diseases Inc
    Somers Point, New Jersey 08244, United States
  • Albert Einstein College of Medicine
    Bronx, New York 10461, United States
  • Erie County Med Ctr
    Buffalo, New York 14215, United States
  • North Shore Univ Hosp / Div of Infectious Diseases
    Manhasset, New York 11030, United States
  • Dr Lawrence Fontana
    New York, New York 10003, United States
  • Liberty Medical / Cabrini Hospital / Dept of Infec Diseases
    New York, New York 10003, United States
  • Howard Grossman
    New York, New York 10011, United States
  • Mount Sinai School of Medicine
    New York, New York 10029, United States
  • Fanno Creek Clinic
    Portland, Oregon 97219, United States
  • Paragon Clinical Research
    Cranston, Rhode Island 02920, United States
  • Coastal Carolina Research Ctr
    Mount Pleasant, South Carolina 29464, United States
  • Central Texas Clinical Research
    Austin, Texas 78705, United States
  • Nelson Tebedo Health Resource Ctr
    Dallas, Texas 75219, United States
  • Amelia Ct Clinic
    Dallas, Texas 75235, United States
  • Univ TX Galveston Med Branch
    Galveston, Texas 77555, United States
  • Houston Clinical Research Network
    Houston, Texas 77006, United States
  • Diversified Med Practices, PA
    Houston, Texas 77027, United States
  • Walter Gaman
    Irving, Texas 75038, United States
  • Swedish Med Ctr / Dr Peter Shalit
    Seattle, Washington 98104, United States
  • FUNCEI
    Buenos Aires, Argentina
  • Fundacion HUES
    Buenos Aires, Argentina
  • Hospital de Agudos JM Ramos Mejia
    Buenos Aires, Argentina
  • Hospital Muniz
    Buenos Aires, Argentina
  • Hospital Interzonal Gen de Agudos Oscar Alende
    Mar del Plata, Argentina
  • Viridae Clinical Sciences / University of British Columbia
    Vancouver, British Columbia, Canada
  • McMaster Univ Med Centre
    Hamilton, Ontario, Canada
  • Montreal Gen Hosp
    Montreal, Quebec, Canada
  • Centre De Recherche En Infectiologie
    Ste Foy, Quebec, Canada
  • Fundacion Arriaran
    Santiago, Chile
  • Instituto Nacional de la Nutricion
    Mexico City, Mexico
  • San Juan Veterans Administration Med Ctr
    San Juan, 009275800, Puerto Rico
07

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 24, 2005, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT00006208
Lead sponsor
Triangle Pharmaceuticals
First posted
Aug 31, 2001
Start date
Aug 2000
Last update
Jun 24, 2005
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jun 2006. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Efavirenz · Emtricitabine · Stavudine · Didanosine

Start the discussion